Edwards Lifesciences (NYSE:EW) traded lower in the premarket on Thursday after Wolfe Research downgraded the heart device ...

Geneos Wealth Management Inc. decreased its stake in shares of Edwards Lifesciences Co. (NYSE:EW – Free Report) by 2.3% ...

Brighton Jones LLC purchased a new position in Edwards Lifesciences Co. (NYSE:EW – Free Report) in the fourth quarter, ...

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”) ...

Wolfe Research downgraded Edwards Lifesciences (EW) to Underperform from Peer Perform with a $60 price target The firm says its core ...

Today, Benzinga's options scanner spotted 8 options trades for Edwards Lifesciences. This is not a typical pattern. The ...

Edwards Lifesciences Corp. engages in the patient ... Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart and Critical Care. The Transcatheter ...

$390,000 of EDWARDS LIFESCIENCES LLC lobbying was just disclosed ... guidance Policies promoting medical innovation Heart Valve Disease Awareness FDA Reauthorization for 2022/FDA User Fees ...

Edwards Lifesciences Corp (EW) stock saw a modest uptick, ending the day at $68.99 which represents a slight increase of $0.06 or 0.09% from the prior close of $68.93. The stock opened at $68.64 and ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 1.79% of ...

In a report released yesterday, Lee Hambright from Bernstein maintained a Hold rating on Edwards Lifesciences (EW – Research Report). The ...